Form 4: PTC Therapeutics CFO Pierre Gravier Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


Pierre Gravier, CFO of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

  • On February 19, 2025, Pierre Gravier, the Chief Financial Officer of PTC Therapeutics, sold 1,168 shares of common stock at a price of $50.096 per share.
  • On February 20, 2025, Gravier sold an additional 1,167 shares of common stock at a price of $50.124 per share.
  • These sales were executed to cover tax withholding obligations associated with the vesting of 4,750 RSUs from a February 15, 2024 grant of 19,000 RSUs and the vesting of 1,550 RSUs from a February 15, 2024 grant of 3,100 RSUs.
  • Following these transactions, Gravier directly owns 74,436 shares of PTC Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales for tax purposes, so it doesn't carry a strong positive or negative sentiment.

Industry Context

Sales of shares to cover tax obligations upon vesting of RSUs are a common practice among corporate executives. This activity is routinely disclosed through SEC filings like Form 4.

Stakeholder Impact

  • The stock sales may have a minor dilutive effect on existing shareholders, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates

DateDescription
02/15/2024Date of RSU grants (19,000 RSUs and 3,100 RSUs) that triggered the tax obligations.
02/19/2025Date of first stock sale (1,168 shares).
02/20/2025Date of second stock sale (1,167 shares).
02/21/2025Date of signature on the Form 4 filing.

Keywords

PTC Therapeutics, Pierre Gravier, CFO, stock sale, Form 4, RSUs, tax obligations, insider trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.